Evidence map›Paper›PMID 29247171›Full record

ArticleScientific reports2017

Computer-Aided Nodule Assessment and Risk Yield (CANARY) may facilitate non-invasive prediction of EGFR mutation status in lung adenocarcinomas.

Ryan Clay, Benjamin R Kipp, Sarah Jenkins, Ron A Karwoski, Fabien Maldonado, Srinivasan Rajagopalan, Jesse S Voss, Brian J Bartholmai, Marie Christine Aubry, Tobias Peikert

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Integrated Biomarkers for the Management of Indeterminate Pulmonary Nodules.American journal of respiratory and critical care medicine · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Ryan ClayPulmonary & Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.
Benjamin R KippLaboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.
Sarah JenkinsBiomedical Statistics & Informatics, Mayo Clinic, Rochester, MN, USA.
Ron A KarwoskiBiomedical Imaging Resource, Mayo Clinic, Rochester, MN, USA.
Fabien MaldonadoAllergy, Pulmonary & Critical Care Medicine, Vanderbilt University, Nashville, TN, USA.
Srinivasan RajagopalanBiomedical Imaging Resource, Mayo Clinic, Rochester, MN, USA.
Jesse S VossLaboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.
Brian J BartholmaiThoracic Radiology, Mayo Clinic, Rochester, MN, USA.
Marie Christine AubryLaboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.
Tobias PeikertPulmonary & Critical Care Medicine, Mayo Clinic, Rochester, MN, USA. Peikert.Tobias@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic in Florida · USMayo Clinic · USVanderbilt University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Computer-Aided Nodule Assessment and Risk Yield (CANARY) is quantitative imaging analysis software that predicts the histopathological classification and post-treatment disease-free survival of patients with adenocarcinoma of the lung. CANARY characterizes nodules by the distribution of nine color-coded texture-based exemplars. We hypothesize that quantitative computed tomography (CT) analysis of the tumor and tumor-free surrounding lung facilitates non-invasive identification of clinically-relevant mutations in lung adenocarcinoma. Comprehensive analysis of targetable mutations (50-gene-panel) and CANARY analysis of the preoperative (≤3 months) high resolution CT (HRCT) was performed for 118 pulmonary nodules of the adenocarcinoma spectrum surgically resected between 2006-2010. Logistic regression with stepwise variable selection was used to determine predictors of mutations. We identified 140 mutations in 106 of 118 nodules. TP53 (n = 48), KRAS (n = 47) and EGFR (n = 15) were the most prevalent. The combination of Y (Yellow) and G (Green) exemplars, fibrosis within the surrounding lung and smoking status were the best discriminators for an EGFR mutation (AUC 0.77 and 0.87, respectively). None of the EGFR mutants expressing TP53 (n = 5) had a good prognosis based on CANARY features. No quantitative features were significantly associated with KRAS mutations. Our exploratory analysis indicates that quantitative CT analysis of a nodule and surrounding lung may noninvasively predict the presence of EGFR mutations in pulmonary nodules of the adenocarcinoma spectrum.

Indexed as

Adenocarcinoma of LungAdultAgedAged, 80 and overDiagnosis, Computer-AssistedDisease-Free SurvivalErbB ReceptorsFemaleHumansLogistic ModelsLungLung NeoplasmsMaleMiddle AgedMultiple Pulmonary NodulesMutationEGFR protein, humanErbB ReceptorsKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID29247171
PMCPMC5732170
OpenAlexW2775805938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.